18,267 resources
By Version
By Authority
Start Prev Rows 8000 - 8200 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth |
|---|---|---|---|---|---|---|---|---|
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.287 | Varicella (Organism or Substance in Lab Results) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.289 | Carbon Monoxide Poisoning (Disorders) (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.293 | Toxic Effects of Lead (Disorders) (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.297 | Measles (Tests for measles virus Nucleic Acid) | active | 2025-03 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.299 | Measles (Tests for measles virus IgM Antibody) | active | 2025-03 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.300 | Meningococcal Disease (Organism or Substance in Lab Results) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.301 | Shigellosis (Tests for Shigella species by Culture and Identification Method) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.307 | Leptospirosis (Tests for Leptospira IgM Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.308 | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.310 | Bacteria (Tests by Culture and Identification Method) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.311 | Viruses (Tests by Culture and Identification Method) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.316 | Rubella (Tests for rubella virus IgM Antibody) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.317 | Shigellosis (Tests for Shigella species Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.319 | Fungi (Tests by Culture and Identification Method) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.322 | Pesticide Related Illness (Disorders) (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.329 | Apnea (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.330 | Apnea (ICD10CM) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.333 | Shigellosis (Organism or Substance in Lab Results) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.335 | Influenza (Tests for influenza A virus by Culture and Identification Method) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.336 | Influenza (Tests for influenza A or B virus Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.340 | Influenza (influenza A or B virus in Lab Results) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.341 | Campylobacteriosis (Organism or Substance in Lab Results) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.342 | Campylobacteriosis (Tests for Campylobacter species by Culture and Identification Method) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.343 | Campylobacteriosis (Tests for Campylobacter species Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.344 | Campylobacteriosis (Tests for Campylobacter species Antigen) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.349 | Hepatitis A (Tests for hepatitis A virus IgM Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.353 | Diarrhea (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.356 | HIV Infection (Organism or Substance in Lab Results) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.359 | Botulism (Disorders) (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.362 | Hansen’s Disease (Disorders) (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.365 | Silicosis (Disorders) (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.366 | Silicosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.371 | Cryptosporidiosis (Organism or Substance in Lab Results) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.372 | Cryptosporidiosis (Tests for Cryptosporidium species Nucleic Acid) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.375 | Cyclosporiasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.376 | Cyclosporiasis (Tests for Cyclospora cayetanensis Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.379 | Giardiasis (Tests for Giardia species Nucleic Acid) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.384 | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.386 | Vibriosis (Organism or Substance in Lab Results) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.388 | Vibriosis (Tests for Vibrionaceae species [except Toxigenic Vibrio cholera O1 and O139] Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.390 | Trichinellosis (Tests for Trichinella species Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.395 | Syphilis (Disorders) (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.396 | Syphilis (Disorders) (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.398 | Hepatitis C Virus Infection (Tests for hepatitis C virus Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.399 | Hepatitis C Virus Infection (Tests for hepatitis C virus Antigen) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.40 | STEC Infection (Disorders) (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.400 | Hepatitis B Virus Infection (Tests for hepatitis B virus IgM Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.401 | Hepatitis B Virus Infection (Tests for hepatitis B virus surface Antigen) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.403 | Hepatitis B Virus Infection (Tests for hepatitis B virus Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.405 | Hantavirus Infection and Diseases (Disorders) (ICD10CM) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.407 | Hepatitis C Virus Infection (Tests for hepatitis C virus Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.408 | Hepatitis B Virus Infection (Organism or Substance in Lab Results) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.422 | Tuberculosis (Disorders) (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.427 | STEC Infection (Tests for Shiga toxin genes, or STEC, EHEC, or E. coli O157 Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.43 | Gonorrhea [Cervicitis Urethritis] (Disorders) (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.436 | Coccidioidomycosis (Tests for Coccidioides species IgM Antibody) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.437 | Coccidioidomycosis (Tests for Coccidioides species Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.438 | Coccidioidomycosis (Tests for Coccidioides species Antigen) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.44 | Gonorrhea [Cervicitis Urethritis] (Disorders) (ICD10CM) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.445 | Legionellosis (Tests for Legionella species Antigen) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.446 | Legionellosis (Tests for Legionella species Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.451 | Tuberculosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.460 | HIV Infection or AIDS (Disorders) (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.464 | Malaria (Tests for Plasmodium species Nucleic Acid) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.468 | Leptospirosis (Tests for Leptospira Nucleic Acid) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.471 | Leptospirosis (Tests for Leptospira Antibody [Quantitative] by Agglutination) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.472 | Leptospirosis (Tests for Leptospira Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.476 | Babesia species (Tests by Microscopic Observation in Blood) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.478 | Anthrax (Tests for Bacillus anthracis by Culture and Identification Method) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.479 | Anthrax (Tests for Bacillus anthracis Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.48 | Salmonellosis (Disorders) (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.480 | Anthrax (Tests for Bacillus anthracis Antigen) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.481 | Anthrax (Tests for Bacillus anthracis Antibody) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.494 | Ehrlichiosis (Organism or Substance in Lab Results) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.496 | Q Fever (Tests for Coxiella burnetii IgM IgG Antibody [Excluding Quantitative IFA Tests for IgG Antibody against Phase I or II Antigen]) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.500 | Q Fever (Tests for Coxiella burnetii Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.505 | Toxic Shock Syndrome (TSS) (Disorders) (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.507 | Toxic Shock Syndrome (TSS) (Disorders) (ICD10CM) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.512 | Brucellosis (Tests for Brucella species Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.515 | Brucellosis (Tests for Brucella species Antibody [Quantitative]) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.516 | Brucellosis (Organism or Substance in Lab Results) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.519 | Dengue Virus Infection (Tests for dengue virus Nucleic Acid) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.523 | Dengue Virus Infection (Tests for dengue virus Antigen) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.524 | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Quantitative]) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.525 | Dengue Virus Infection (Tests for dengue virus IgM Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.527 | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Qualitative]) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.530 | Borrelia species (Tests for Nucleic Acid) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.531 | Lyme Disease (Tests for Borrelia burgdorferi IgM IgG Antibody by Immunoblot) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.532 | Lyme Disease (Tests for Borrelia burgdorferi Antibody by Immunoassay) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.534 | Smallpox (Organism or Substance in Lab Results) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.548 | St. Louis Encephalitis Virus Infection (Tests for Saint Louis encephalitis virus Antibody [Qualitative]) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.550 | Syphilis (Tests for Treponema pallidum Nucleic Acid) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.553 | Anaplasma species (Tests by Microscopic Observation) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.555 | Yellow Fever (Tests for yellow fever virus Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.557 | Yellow Fever (Tests for yellow fever virus Antibody [Quantitative]) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.56 | Diarrhea (ICD10CM) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.560 | West Nile Virus Infection (Tests for West Nile virus Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.569 | Plague (Tests for Yersinia pestis Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.58 | Pertussis (Tests for Bordetella pertussis Nucleic Acid) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.595 | Tularemia (Tests for Francisella tularensis Nucleic Acid) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.598 | Tularemia (Tests for Francisella tularensis Antibody) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.6 | Diphtheria (Disorders) (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.605 | Organisms (Tests by Microscopic Observation by Acid Fast Stain) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.606 | Tuberculosis (Organism or Substance in Lab Results) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.614 | Pertussis (Tests for Bordetella pertussis Toxin Antibody) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.621 | Inspiratory Whoop (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.632 | Chlamydia trachomatis Infection [Secondary Sites Complications] (Disorders) (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.645 | Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.648 | Vomiting (ICD10CM) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.650 | Jaundice (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.652 | Bacteria (Tests in Specimen from Normally Sterile Site by Culture and Identification Method) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.660 | Hypertonia [Excluding Congenital Hypertonia] (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.662 | Chest Pain (ICD10CM) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.663 | Erythema Nodosum (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.664 | Congenital Zika Syndromes (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.665 | Congenital Zika Syndromes (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.666 | Guillain Barré syndrome (Disorders) (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.668 | Rash (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.671 | Fever (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.672 | Arthralgia (SNOMED) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.673 | Arthralgia (ICD10CM) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.674 | Conjunctivitis (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.675 | Conjunctivitis (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.676 | Pregnant (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.677 | Postpartum (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.678 | Postpartum (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.679 | Hearing Loss (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.680 | Abdominal Pain (ICD10CM) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.681 | Abdominal Pain (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.686 | Erythema Multiforme (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.687 | Myalgia (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.689 | Periorbital Edema (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.691 | Eosinophilia (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.692 | Eosinophilia (SNOMED) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.70 | Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi by Culture and Identification Method) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.702 | Weight Loss (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.705 | Syphilis (Tests for Treponemal or Non Treponemal Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.709 | Cough [Non Productive] (SNOMED) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.71 | Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi Nucleic Acid) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.711 | Wound Infection (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.712 | Pneumonia (ICD10CM) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.713 | Sepsis [Septicemia] [Unspecified Organism] (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.714 | Sepsis [Septicemia] [Unspecified Organism] (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.715 | Meningitis (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.717 | Cellulitis (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.718 | Cellulitis (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.719 | Myositis [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.720 | Myositis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.721 | Otitis Media (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.722 | Otitis Media (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.723 | Otitis Externa (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.724 | Otitis Externa (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.727 | Acute Upper Respiratory Illness (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.728 | HIV Infection (Tests for HIV Nucleic Acid [Qualitative]) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.730 | HIV Infection (Tests for HIV Antibody) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.733 | Perinatal Hepatitis B Virus Infection (Disorders) (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.744 | Coccidioidomycosis (Tests for Coccidioides species IgG Antibody) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.746 | Treponema pallidum (Tests by Microscopic Observation) | active | 2022-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.750 | Chest Pain (SNOMED) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.755 | Acute Upper Respiratory Illness (ICD10CM) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.756 | Purpura (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.757 | Muscle Spasms (ICD10CM) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.758 | Muscle Spasms (SNOMED) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.762 | Mumps (Test Panels for mumps virus IgM IgG Antibody) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.763 | Parotitis [Unspecified Cause] (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.764 | Mumps (Tests for mumps virus IgG Antibody) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.765 | Aseptic Meningitis (Disorders) (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.766 | Encephalitis (Disorders) (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.767 | Hearing Loss (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.770 | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.773 | Invasive Haemophilus influenzae Disease (Tests for Haemophilus influenzae Nucleic Acid in Specimen from Normally Sterile Site) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.777 | Mastitis (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.779 | Pancreatitis (SNOMED) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.780 | Pancreatitis (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.782 | Rubella (Test Panels for rubella virus IgM IgG Antibody) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.785 | Opioid Overdose and Poisoning (Tests for Opioids [Qualitative]) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.789 | Purpura (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.79 | Campylobacteriosis (Disorders) (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.792 | Novel Influenza A Virus Infection (Disorders) (ICD10CM) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.793 | Novel Influenza A Virus Infection (Disorders) (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.794 | Sore Throat (SNOMED) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.795 | Influenza (influenza A virus in Lab Results) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.796 | Influenza (Novel influenza A virus in Lab Results) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.797 | Influenza (Tests for influenza A or B virus by Culture and Identification Method) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.798 | Influenza (Tests for influenza A virus Nucleic Acid) | active | 2025-02 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.799 | Influenza (Tests for influenza A virus Antigen) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.802 | Influenza (Tests for Novel influenza A virus Nucleic Acid) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.803 | Tests by Microscopic Observation in Tissue by H&E or PAS Stain | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.808 | Headache (ICD10CM) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.809 | Headache (SNOMED) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.810 | Backache (SNOMED) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.811 | Backache (ICD10CM) | active | 2024-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.815 | NU_Anaplasmosis (Tests for Anaplasma species Antibody [Qualitative]) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.816 | Rubella (Tests for rubella virus IgG Antibody [Ratio] in Serum) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.818 | Measles (Tests for measles virus IgG Antibody [Ratio] in Serum) | active | 2025-03 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.820 | Rubella (Tests for rubella virus IgG Antibody [Quantitative] in Serum) | active | 2024-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.822 | Pneumoconiosis (Unspecified) (ICD10CM) | active | 2023-06 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.823 | Pneumoconiosis (Unspecified) (SNOMED) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.824 | Computerized Tomography of Chest (Imaging) | active | 2023-01 | hl7 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.830 | Poliovirus Infection (Tests for Poliovirus Antibody Titer in Serum Specimen) | active | 2025-02 | hl7 |
FHIR